Determination of target in-vitro drug release profile for extended release formulation of acyclovir through pharmacokinetic simulations

Anti-Infective Agents

Volumn 11, Issue 2, 2013, Pages 204-211

  Sankar, R ^a   Jain, Subheet Kumar ^b  

^a PUNJABI UNIVERSITY   (India)

^b GURU NANAK DEV UNIVERSITY   (India)

Author keywords

Acyclovir; Conventional delivery limitations; Extended release; Oral delivery; Simulation model; Target in vitro drug release

Indexed keywords

ACICLOVIR;

ARTICLE; BLOOD LEVEL; COMPARATIVE STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; FEASIBILITY STUDY; IN VITRO STUDY; MOLECULAR WEIGHT; PARAMETERS; SIMULATION; SINGLE DRUG DOSE;

EID: 84878786587     PISSN: 22113525     EISSN: 22113533     Source Type: Journal    
DOI: 10.2174/2211352511311020014     Document Type: Article

References (26)

1. Balfour, H.H. In: The antimicrobial agents annual 3, P. K. Peterson and J. Verhoef Ed.; Elsevier Science Publishing Inc., New York, 1988, pp. 345-360.
2. ®-US prescribing information, 2005. URL: https://www.gsksource.com/gskprm/htdocs/documents/ZOVIRAX-ORAL.PDF. (Accessed Last on March 14, 2012).
3. NGC (National Guideline Clearing House). National guideline for the management of genital herpes, 2007. 2007, URL: http://www.guideline.gov/content.aspx?id=12214. (Accessed Last on March 14, 2012).
4. Chiou, W.L.; Barve, A. Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm. Res., 1998, 15(11), 1792-1795.
5. Lewis, L.D.; Fowle, A.S.E.; Bittiner, S.B.; Bye, A.; Isaacs, P.E.T. Human gastrointestinal absorption of acyclovir from tablet duodenal infusion and sipped solution. Br. J. Clin. Pharmacol., 1986, 21(4), 459-462.
6. Meadows, K.C.; Dressman J.B. Mechanism of acyclovir uptake in rat jejunum. Pharm Res., 1990, 7(3), 299-303.
7. O'Brien, J.J.; Campoli-Richards, D.M. Acyclovir: An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs, 1989, 37(3), 233-309.
8. Ritschel, W.A. Biopharmaceutic and pharmacokinetic aspects in the design of controlled release peroral drug delivery systems. Drug Dev. Ind. Pharm., 1989, 15(6-7), 1073-1103.
9. nd ed.; Informa Healthcare: Newyork, 1982.
10. Ritschel, W.A.; Kearns, G.L. Handbook of Basic Pharmacokinetics Including Clinical Applications, 6th ed.; American Pharmacists Association: Washington, D.C., 2007.
11. Chung, M.; Vashi, V.; Puente, J.; Sweeney, M.; Meredith, P. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br. J. Clin. Pharmacol., 1999, 48, 678-687.
12. Costa, P.; Lobo, M.S. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci., 2001, 13(2), 123-133.
13. Sood, A.; Panchagnula, R. Design of controlled release delivery systems using a modified pharmacokinetic approach: a case study for drugs having a short elimination half-life and a narrow therapeutic index. Int. J. Pharm., 2003, 261(1-2), 27-41.
14. Verma, R.K.; Kaushal, A.M.; Garg, S. Development and evaluation of extended release formulations of isosorbide mononitrate based on osmotic technology. Int. J. Pharm., 2003, 263(1-2), 9-24.
15. Gandhi, R.; Kaul, C.L.; Panchagnula, R. Pharmacokinetic evaluation of an azithromycin controlled release dosage form in healthy human volunteers: a single dose study. Int. J. Pharm., 2004, 270 (1-2), 1-8.
16. Sood, A.; Ashokraj, Y.; Panchagnula, R. Use of extrusion- spheronization to develop controlled-release dosage forms for dilti-azem hydrochloride. Pharm. Tech., 2004, 4, 62-85.
17. Shojaei, A.H.; Berner, B.; Li, X. Transbuccal Delivery of Acy-clovir: I. In Vitro Determination of Routes of Buccal Transport. Pharm. Res., 1998, 15(8), 1182-1188.
18. Dhaliwal, S.; Jain, S.; Singh, H.P.; Tiwary, A.K. Mucoadhesive microspheres for gastroretentive delivery of acyclovir: In vitro and In vivo evaluation. AAPS J, 2008, 10(2), 322-330.
19. Fuertes, I.; Miranda, A.; Millan, M.; Caraballo, I. Estimation of the percolation thersholds in acyclovir hydrophilic matrix tablets. Eur. J. Pharm. Biopharm. 2006, 64(3), 336-342.
20. Garg, R.; Gupta, G.D. Preparation and evaluation of gastroretentive floating tablets of acyclovir. Curr. Drug. Delivery, 2009, 6(5); 437-443.
21. El Gamal, S.S.; Naggar, V.F.; Allam, A.N. Optimization of acy-clovir oral tablets based on gastroretention technology: factorial design analysis and physicochemical characterization studies. Drug Dev. Ind. Pharm. 2011, 37(7), 855-867.
22. Gromova, L.I.; Hoichman, D.; Sela, J. Gastroretentive sustained release acyclovir tablets based on synergistically interacting poly-saccharides. Pharmaceutical Chemistry Journal, 2007, 41(12), 656-658.
23. Gröning, R.; Berntgen, M.; Georgarakis, M. Acyclovir serum concentrations following peroral administration of magnetic depot tablets and the influence of extracorporal magnets to control gastrointestinal transit. Eur. J. Pharm. Biopharm., 1998, 46, 285-291.
24. Ahmed, F.J.; Drabu, S.; Khatri, S.; Babu, S. Formulation and evaluation of acyclovir capsules. Int. J. Drug Develop Res., 2011, 3(4): 162-167.
25. Singhal, P., Kumar, K., Pandey, M., Saraf, S.A., Evaluation of Acyclovir Loaded oil entrapped Calcium alginate Beads Prepared by Ionotropic Gelation Method. Int. J. Chem. Tech. Res., 2010, 2(4), 2076-2085.
26. Junyaprasert, V.B.; Pornsuwannapha, S. Floating properties and release characteristics of hollow microspheres of acyclovir. Drug Deliv. 2008, 15, 331-341.